Division of Cosmo Pharmaceuticals NV
Latest From BioXell SPA
An early-stage French company focused on developing a new treatment for sepsis says it has raised the largest series A financing in Europe to date in 2014. Inotrem, which was set up in 2013 around research work done at the University of Lorraine Medical School in Nancy, has completed a €18m fundraising led by Edmond de Rothschild Investment Partners and Sofinnova Partners.
Glenmark Pharmaceuticals has in-licensed the private Italian firm Lay Line Genomics' (LLG) intellectual property portfolio in the tyrosine kinase A (TrkA) field. The agreement includes LLG's BXL1H5, a monoclonal antibody that binds specifically to TrkA receptors.
A foreign exchange loss on the put option issued as part of its recent acquisition of BioXell dragged Italian firm Cosmo Pharmaceuticals' net profit down by 75% to €500,000 in the first half of 2010.
BioXell, which is in the process of being acquired by fellow Italian firm Cosmo Pharmaceuticals, has ended efforts to divest its remaining technology assets.
- Large Molecule
- Therapeutic Areas
- Neurology, Nervous System
- Western Europe
- Parent & Subsidiaries
- Cosmo Pharmaceuticals NV
- Senior Management
- Niels Ackermann, CEO
- Contact Info
Phone: (39) 02 21049 51
Via Fratelli Cervi, Centro Direzionale
di Milano 2
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.